Congressional Research Service Explains Legal Framework of DEA's 7-OH Temporary Scheduling

Why it matters

The CRS analysis lays out exactly what the DEA action does and does not control, what legal tools Congress could use to make scheduling permanent, and how the 7-OH situation compares to prior temporary scheduling actions like fentanyl-related substances. Policymakers and industry need this framework to understand what comes next.

The big picture

On July 1, 2026, the DEA filed two Federal Register notices intending to temporarily place 7-hydroxymitragynine (7-OH) above a specified threshold — plus three synthetic derivatives (mitragynine pseudoindoxyl, MGM-15, and MGM-16) — in Schedule I of the Controlled Substances Act. The CRS Legal Sidebar published July 17 provides Congress with a nonpartisan legal overview of the action, its scope, and its limits.

Key findings

• The temporary scheduling covers 7-OH above 0.05% concentration in the kratom plant, or above 0.05% or 1 mg in processed products such as extracts, gummies, tablets, and shots
• Natural leaf kratom and products with 7-OH below the threshold are explicitly excluded from the temporary scheduling
• Three synthetic derivatives — mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16 — are being scheduled without any threshold limits
• The temporary order will be effective for up to two years and could be extended one additional year if permanent scheduling is pending
• Congress could enact legislation to make scheduling permanent — as it did with fentanyl-related substances — or could alternatively pursue broader kratom regulation under the Federal Food, Drug, and Cosmetic Act

What they say

The CRS notes that unlike the classwide fentanyl-related substance scheduling, "with four substances at issue rather than thousands, DEA may be able to undertake the required fact-finding for all the substances," suggesting permanent administrative scheduling of 7-OH is feasible without an act of Congress.

Bottom line

The DEA's 7-OH temporary scheduling is legally narrow — targeting concentrated products above a threshold while leaving natural leaf kratom untouched — but Congress retains authority to expand or modify the regulatory framework at any time.